BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors
{{output}}
The anilino-quinazoline derivative BIBW-2992, which is being developed by Boehringer Ingelheim Corp for the potential treatment of solid tumors, is an oral dual receptor tyrosine kinase inhibitor of human EGF receptor (EGFR) and human epidermal growth factor r... ...
